Avivagen Inc., formerly Chemaphor Inc., is a development-stage company. The Company develops small-molecule compound discoveries for commercialization in markets in distinct biotechnology sectors. The Company focuses is on a product developed from the oxidation of carotenoids; OxC-beta, a product being developed for several applications, including animal feed, human and pet nutraceuticals, veterinary, and human skin care. Its Oximunol Chewables contain OxC-�, a mixture of carotenoid oxidation products. OxC-beta is obtained through the spontaneous, full oxidation of �-carotene. Oximunol Chewables contains OxC-beta formulated for use in companion dogs to optimize gastrointestinal health. The Company�s focus on natural health optimizers (NHO) includes pet wellness, livestock health and productivity enhancement, and human health and wellness.